We are live on ! Find out more
VYNT

Vyant Bio, Inc. Common Stock
VYNT

Delisted

VYNT was delisted on the 12th of May, 2023.

Back to rankings

26 hedge funds and large institutions have $949K invested in Vyant Bio, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

24% more funds holding

Funds holding: 21 → 26 (+5)

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

36% less capital invested

Capital invested by funds: $1.47M → $949K (-$523K)

Holders
26
Holders Change
+5
Holders Change %
+23.81%
% of All Funds
0.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
3
Reduced
3
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors
North Carolina
+$153K
2
Citadel Advisors
Citadel Advisors
Florida
+$16.3K
3
TSS
Two Sigma Securities
New York
+$16.3K
4
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors
Iowa
+$16.2K
5
YIH
Y-Intercept (HK)
Hong Kong
+$12.5K

Top Sellers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
-$7.39K
2
UBS Group
UBS Group
Switzerland
-$2.61K
3
Wells Fargo
Wells Fargo
California
-$26
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$422K – – –
CAPTRUST Financial Advisors
2
CAPTRUST Financial Advisors
North Carolina
$113K +$153K +40,535 +405,350%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$108K – – –
BlackRock
4
BlackRock
New York
$74K – – –
State Street
5
State Street
Massachusetts
$42K – – –
Northern Trust
6
Northern Trust
Illinois
$24K – – –
JSC
7
Jackson Square Capital
California
$17K – – –
US Bancorp
8
US Bancorp
Minnesota
$14K – – –
Renaissance Technologies
9
Renaissance Technologies
New York
$12K +$378 +100 +2%
Cambridge Investment Research Advisors
10
Cambridge Investment Research Advisors
Iowa
$12K +$16.2K +4,292 New
TSS
11
Two Sigma Securities
New York
$12K +$16.3K +4,307 New
Citadel Advisors
12
Citadel Advisors
Florida
$12K +$16.3K +4,312 New
CCB
13
Country Club Bank
Missouri
$11K – – –
Morgan Stanley
14
Morgan Stanley
New York
$11K – – –
NP
15
NorthRock Partners
Minnesota
$11K – – –
YIH
16
Y-Intercept (HK)
Hong Kong
$9.27K +$12.5K +3,321 New
VF
17
Virtu Financial
New York
$9K -$7.39K -1,958 -38%
UBS Group
18
UBS Group
Switzerland
$8K -$2.61K -690 -20%
AWM
19
AE Wealth Management
Kansas
$8K – – –
CCM
20
Carlson Capital Management
Minnesota
$7K – – –
Susquehanna International Group
21
Susquehanna International Group
Pennsylvania
$7K +$9.55K +2,529 New
Mariner
22
Mariner
Kansas
$6K +$7.76K +2,055 New
Wells Fargo
23
Wells Fargo
California
– -$26 -7 -19%
Fidelity Investments
24
Fidelity Investments
Massachusetts
– +$4 +1 +25%
Osaic Holdings
25
Osaic Holdings
Arizona
– +$91 +24 New

VYNT Hedge Fund Activity: Q3 2022 in Review

26 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Vyant Bio, Inc. Common Stock (VYNT) for Q3 2022, worth a combined $949K — down 36% from $1.47M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new VYNT positions and 0 closed out — a net gain of 7 holders — while 3 added to existing stakes and 3 trimmed.

The largest buyer was CAPTRUST Financial Advisors, adding an estimated $153K. The largest seller was Virtu Financial, cutting an estimated $7.39K.

  • 26 institutional investors held Vyant Bio, Inc. Common Stock (VYNT) as of Q3 2022, up from 21 in Q2 2022.
  • Funds reported $949K of Vyant Bio, Inc. Common Stock stock for Q3 2022, down 36% quarter-over-quarter.
  • 7 funds opened new Vyant Bio, Inc. Common Stock positions in Q3 2022 and 0 closed out, a net change of +7 holders.
  • The largest Vyant Bio, Inc. Common Stock buyer in Q3 2022 was CAPTRUST Financial Advisors, an estimated $153K added.
  • The largest Vyant Bio, Inc. Common Stock seller in Q3 2022 was Virtu Financial, an estimated $7.39K sold.

Based on aggregated 13F filings for Q3 2022.